Cardiac Failure Review最新文献_第6页

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly 老年人射血分数降低的心力衰竭的药物治疗

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2021.14

Ivan Milinković, M. Polovina, A. Coats, G. Rosano, P. Seferovic

{"title":"Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly","authors":"Ivan Milinković, M. Polovina, A. Coats, G. Rosano, P. Seferovic","doi":"10.15420/cfr.2021.14","DOIUrl":"https://doi.org/10.15420/cfr.2021.14","url":null,"abstract":"The aging population, higher burden of predisposing conditions and comorbidities along with improvements in therapy all contribute to the growing prevalence of heart failure (HF). Although the majority of trials have not demonstrated age-dependent heterogeneity in the efficacy or safety of medical treatment for HF, the latest trials demonstrate that older participants are less likely to receive established drug therapies for HF with reduced ejection fraction. There remains reluctance in real-world clinical practice to prescribe and up-titrate these medications in older people, possibly because of (mis)understanding about lower tolerance and greater propensity for developing adverse drug reactions. This is compounded by difficulties in the management of multiple medications, patient preferences and other non-medical considerations. Future research should provide a more granular analysis on how to approach medical and device therapies in elderly patients, with consideration of biological differences, difficulties in care delivery and issues relevant to patients’ values and perspectives. A variety of approaches are needed, with the central principle being to ‘add years to life – and life to years’. These include broader representation of elderly HF patients in clinical trials, improved education of healthcare professionals, wider provision of specialised centres for multidisciplinary HF management and stronger implementation of HF medical treatment in vulnerable patient groups.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45742472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 吡非尼酮治疗特发性肺纤维化及其他疾病

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2021.30

A. Aimo, G. Spitaleri, D. Nieri, L. Tavanti, C. Meschi, G. Panichella, J. Lupón, F. Pistelli, L. Carrozzi, A. Bayés‐Genís, M. Emdin

引用次数: 14

Cell Therapy in Heart Failure with Preserved Ejection Fraction 保留射血分数的心力衰竭细胞治疗

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2021.21

S. Frljak, G. Poglajen, B. Vrtovec

引用次数: 3

Aortic Pulsatility Index: A New Haemodynamic Measure with Prognostic Value in Advanced Heart Failure 主动脉搏动指数：一种对晚期心力衰竭具有预后价值的新血液动力学指标

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2022.09

T. Deis, K. Rossing, F. Gustafsson

{"title":"Aortic Pulsatility Index: A New Haemodynamic Measure with Prognostic Value in Advanced Heart Failure","authors":"T. Deis, K. Rossing, F. Gustafsson","doi":"10.15420/cfr.2022.09","DOIUrl":"https://doi.org/10.15420/cfr.2022.09","url":null,"abstract":"Aim: To test if the newly described haemodynamic variable, aortic pulsatility index (API), predicts long-term prognosis in advanced heart failure (HF). Methods: A single-centre study on 453 HF patients (median age: 51 years; left ventricular ejection fraction [LVEF]: 19% ± 9%) referred for right heart catheterisation. API was calculated as pulse pressure/pulmonary capillary wedge pressure. Results: Log(API) correlated significantly with central venous pressure (CVP; p<0.001) and cardiac index (p<0.001) in univariable regression analysis. CVP remained associated with log(API) in a multivariable analysis including cardiac index, heart rate, log(NT-proBNP [N-terminal proB-type natriuretic peptide]), LVEF, New York Heart Association (NYHA) class III or IV and sex (p=0.01). In univariable Cox models, log(API) was a significant predictor of freedom from the combined endpoint of death, left ventricular assist device implantation, total artificial heart implantation or heart transplantation (HR 0.33; (95% CI [0.22–0.49]); p<0.001) and all-cause mortality (HR 0.56 (95% CI [0.35–0.90]); p=0.015). After adjusting for age, sex, NYHA class III or IV and estimated glomerular filtration rate in multivariable Cox models, log(API) remained a significant predictor for the combined endpoint (HR 0.33; 95% CI [0.20–0.56]; p<0.001) and all-cause mortality (HR 0.49; 95% CI [0.26–0.96]; p=0.034). Conclusion: API was strongly associated with right-sided filling pressure and independently predicted freedom from the combined endpoint and all-cause mortality.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49575803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Out with the Old and In with the New: Primary Care Management of Heart Failure with Preserved Ejection Fraction 推陈出新：保留射血分数的心力衰竭的初级保健管理

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2021.27

S. Stewart, Amy R Stewart, Laura H. Waite, J. Beilby

引用次数: 3

Multimodality Imaging in Valvular Structural Interventions. 多模态成像在瓣膜结构干预中的应用。

Cardiac Failure Review Pub Date : 2022-01-01 DOI: 10.15420/cfr.2022.10

Karine Grigoryan, Camelia Demetrescu, Ioannis Kasouridis, Olukayode Abiola, Pier Giorgio Masci, Didem Oguz, Giulia Benedetti, Mak SzeMun, Purvi Parwani, Rebecca Preston, Amedeo Chiribiri, Jane Hancock, Tiffany Patterson, Simon Redwood, Bernard Prendergast, Julia Grapsa

引用次数: 1

Adjunctive Techniques for Repair of Ischaemic Mitral Regurgitation. 辅助技术修复缺血性二尖瓣返流。

Cardiac Failure Review Pub Date : 2021-12-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.06

Sigrid L Johannesen, Colin M Barker, Melissa M Levack

{"title":"Adjunctive Techniques for Repair of Ischaemic Mitral Regurgitation.","authors":"Sigrid L Johannesen, Colin M Barker, Melissa M Levack","doi":"10.15420/cfr.2021.06","DOIUrl":"https://doi.org/10.15420/cfr.2021.06","url":null,"abstract":"Ischaemic mitral regurgitation is a complex process with debate in the literature as to the optimal treatment pathway. Multiple therapies are available to alleviate mitral regurgitation including medical management, transcatheter edge-to-edge repair, mitral valve repair and mitral valve replacement. Medical management with goal-directed therapy should be utilised in patients with heart failure and mild-to-moderate regurgitation. Transcatheter approaches are typically used in patients with prohibitive operative risk, although their use is expanding, especially in those with functional mitral regurgitation who are not responding to goal-directed medical therapy. It is generally accepted that patients with mild-to-moderate disease can avoid valve intervention if successful revascularisation is performed. A higher consideration should be given to valve replacement over repair in patients with severe mitral regurgitation in the setting of myocardial ischaemia. Operative course must be personalised to each patient, and continues to develop with improving technologies and ongoing research into optimal treatment.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e20"},"PeriodicalIF":0.0,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/3d/cfr-07-e20.PMC8674630.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolated Left Ventricular Apical Hypoplasia. 孤立性左心室顶端发育不全。

Cardiac Failure Review Pub Date : 2021-12-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.24

Abhishek Dattani, Rachana Prasad

引用次数: 2

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. 空白填补:快速启动和最佳滴定综合疾病改善药物治疗心力衰竭与降低射血分数的基本原理。

Cardiac Failure Review Pub Date : 2021-11-26 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.18

Nicholas K Brownell, Boback Ziaeian, Gregg C Fonarow

引用次数: 19

Cardiac Sarcoidosis: When and How to Treat Inflammation. 心脏结节病:何时及如何治疗炎症。

Cardiac Failure Review Pub Date : 2021-11-22 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.16

Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala

{"title":"Cardiac Sarcoidosis: When and How to Treat Inflammation.","authors":"Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala","doi":"10.15420/cfr.2021.16","DOIUrl":"https://doi.org/10.15420/cfr.2021.16","url":null,"abstract":"Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e17"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e7/cfr-07-e17.PMC8674699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17